US 12,478,578 B2
Injectable hydrogels for cell delivery to the vitreous
Pierre A. Colombe, Boston, MA (US); Deepti Singh, Boston, MA (US); Myron Spector, Boston, MA (US); and Michael Young, Boston, MA (US)
Assigned to Massachusetts Eye and Ear Infirmary, Boston, MA (US); The Brigham and Women's Hospital, Inc., Boston, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Appl. No. 17/781,076
Filed by Massachusetts Eye and Ear Infirmary, Boston, MA (US); MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
PCT Filed Dec. 3, 2020, PCT No. PCT/US2020/063115
§ 371(c)(1), (2) Date May 31, 2022,
PCT Pub. No. WO2021/113515, PCT Pub. Date Jun. 10, 2021.
Claims priority of provisional application 62/942,928, filed on Dec. 3, 2019.
Prior Publication US 2023/0000762 A1, Jan. 5, 2023
Int. Cl. A61K 9/51 (2006.01); A61K 9/00 (2006.01); A61K 31/045 (2006.01); A61K 31/728 (2006.01); A61P 27/02 (2006.01); C08G 73/02 (2006.01); C08L 79/02 (2006.01)
CPC A61K 9/0051 (2013.01) [A61K 9/0024 (2013.01); A61K 31/045 (2013.01); A61K 31/728 (2013.01); A61P 27/02 (2018.01); C08G 73/02 (2013.01); C08L 79/02 (2013.01)] 20 Claims
 
1. A method of treating an ocular disorder in a subject in need thereof, the method comprising:
administering a therapeutically effective amount of a composition into an eye of the subject,
wherein the composition comprises gelatin hydroxyphenylpropionic acid (gelatin-HPA), hyaluronic acid-tyramine (HA-Tyr), and an ocular cell, and
wherein the composition attaches to an inner portion eye after administration into the eye.